MARC보기
LDR02228nmm uu200409 4500
001000000334132
00520240805175209
008181129s2018 |||||||||||||||||c||eng d
020 ▼a 9780438176782
035 ▼a (MiAaPQ)AAI10828320
035 ▼a (MiAaPQ)washington:18796
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 248032
0820 ▼a 615
1001 ▼a Li, Meng.
24514 ▼a The Real Option Value of Life And Innovation.
260 ▼a [S.l.] : ▼b University of Washington., ▼c 2018
260 1 ▼a Ann Arbor : ▼b ProQuest Dissertations & Theses, ▼c 2018
300 ▼a 99 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
500 ▼a Adviser: Louis Garrison.
5021 ▼a Thesis (Ph.D.)--University of Washington, 2018.
520 ▼a Background: Recent developments in healthcare value assessments have expanded the definition of value for medical technologies. The option value of a life-extending treatment is the opportunity of benefiting from future innovations during the ex
520 ▼a Methods: In the first study, an interrupted time series analysis was conducted using a large administrative claims database to test whether the utilization of existing treatments changed after the disclosures of the then-investigational drug ipi
520 ▼a Results: In the first study, 1,846 metastatic melanoma patients were included. After adjusting for clinical and sociodemographic variables, as well as the underlying time trend, the disclosure of ipilimumab's phase II result was associated with
520 ▼a Conclusion: This dissertation research provided the first empirical evidence of the impact of real option value in cancer treatment decision-making. It was also the first to incorporate option value in an ex ante CEA and estimated its potential
590 ▼a School code: 0250.
650 4 ▼a Pharmaceutical sciences.
690 ▼a 0572
71020 ▼a University of Washington. ▼b Pharmacy.
7730 ▼t Dissertation Abstracts International ▼g 79-12B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0250
791 ▼a Ph.D.
792 ▼a 2018
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T14999150 ▼n KERIS
980 ▼a 201812 ▼f 2019
990 ▼a 관리자